|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hodis E, Watson IR, Kryukov GV, Arold ST,
Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C,
et al: A landscape of driver mutations in melanoma. Cell.
150:251–263. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cancer Genome Atlas Network: Genomic
classification of cutaneous melanoma. Cell. 161:1681–1696. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Flaherty KT, Puzanov I, Kim KB, Ribas A,
McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K and
Chapman PB: Inhibition of mutated, activated BRAF in metastatic
melanoma. N Engl J Med. 363:809–819. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Poulikakos PI, Zhang C, Bollag G, Shokat
KM and Rosen N: RAF inhibitors transactivate RAF dimers and ERK
signalling in cells with wild-type BRAF. Nature. 464:427–430. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hodi FS, O'Day SJ, McDermott DF, Weber RW,
Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel
JC, et al: Improved survival with ipilimumab in patients with
metastatic melanoma. N Engl J Med. 363:711–723. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Larkin J, Chiarion-Sileni V, Gonzalez R,
Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M,
Rutkowski P, et al: Combined nivolumab and ipilimumab or
monotherapy in untreated melanoma. N Engl J Med. 373:23–34. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Robert C, Schachter J, Long GV, Arance A,
Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al:
Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med.
372:2521–2532. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hayward RD: Malignant melanoma and the
central nervous system. A guide for classification based on the
clinical findings. J Neurol Neurosurg Psychiatry. 39:526–530. 1976.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rosenthal G, Gomori JM, Tobias S, Diment J
and Shoshan Y: Unusual cases involving the CNS and nasal sinuses:
Case 1. Primary leptomeningeal melanoma. J Clin Oncol.
21:3875–3877. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Paulus W and Hasselblatt M:
TumorenNeuropathologie. Springer; Berlin-Heidelberg: pp. 481–549.
2012
|
|
12
|
Hsieh YY, Yang ST, Li WH, Hu CJ and Wang
LS: Primary leptomeningeal melanoma mimicking meningitis: A case
report and literature review. J Clin Oncol. 33:e57–e61. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
van de Nes J, Gessi M, Sucker A, Möller I,
Stiller M, Horn S, Scholz SL, Pischler C, Stadtler N, Schilling B,
et al: Targeted next generation sequencing reveals unique mutation
profile of primary melanocytic tumors of the central nervous
system. J Neurooncol. 127:435–444. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wick MR, Swanson PE and Rocamora A:
Recognition of malignant melanoma by monoclonal antibody HMB-45. An
immunohistochemical study of 200 paraffin-embedded cutaneous
tumors. J Cutan Pathol. 15:201–207. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tosaka M, Tamura M, Oriuchi N, Horikoshi
M, Joshita T, Sugawara K, Kobayashi S, Kohga H, Yoshida T and
Sasaki T: Cerebrospinal fluid immunocytochemical analysis and
neuroimaging in the diagnosis of primary leptomeningeal melanoma.
Case report. J Neurosurg. 94:528–532. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sagiuchi T, Ishii K, Utsuki S, Asano Y,
Tsukahara S, Kan S, Fujii K and Hayakawa K: Increased uptake of
technetium-99m-hexamethylpropyleneamine oxime related to primary
leptomeningeal melanoma. AJNR Am J Neuroradiol. 23:1404–1406.
2002.PubMed/NCBI
|
|
17
|
Hoffman HJ and Freeman A: Primary
malignant leptomeningeal melanoma in association with giant hairy
nevi. J Neurosurg. 26:62–71. 1967. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Salgado CM, Basu D, Nikiforova M, Bauer
BS, Johnson D, Rundell V, Grunwaldt LJ and Reyes-Múgica M: BRAF
mutations are also associated with neurocutaneous melanocytosis and
large/giant congenital melanocytic nevi. Pediatr Dev Pathol.
18:1–9. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Flaherty KT, Robert C, Hersey P, Nathan P,
Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, et
al: Improved survival with MEK inhibition in BRAF-mutated melanoma.
N Engl J Med. 367:107–114. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Medina TM and Lewis KD: The evolution of
combined molecular targeted therapies to advance the therapeutic
efficacy in melanoma: A highlight of vemurafenib and cobimetinib.
Onco Targets Ther. 9:3739–3752. 2016.PubMed/NCBI
|
|
21
|
Hamid O, Robert C, Daud A, Hodi FS, Hwu
WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al:
Safety and tumor responses with lambrolizumab (anti-PD-1) in
melanoma. N Engl J Med. 369:134–144. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Margolin K, Ernstoff MS, Hamid O, Lawrence
D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF,
et al: Ipilimumab in patients with melanoma and brain metastases:
An open-label, phase 2 trial. Lancet Oncol. 13:459–465. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wilgenhof S and Neyns B: complete
cytologic remission of V600E BRAF-mutant melanoma-associated
leptomeningeal carcinomatosis upon treatment with dabrafenib. J
Clin Oncol. 33:e109–e111. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pan W, Gu W, Nagpal S, Gephart MH and
Quake SR: Brain tumor mutations detected in cerebral spinal fluid.
Clin Chem. 61:514–522. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang Y, Springer S, Zhang M, McMahon KW,
Kinde I, Dobbyn L, Ptak J, Brem H, Chaichana K, Gallia GL, et al:
Detection of tumor-derived DNA in cerebrospinal fluid of patients
with primary tumors of the brain and spinal cord. Proc Natl Acad
Sci USA. 112:9704–9709. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
De Mattos-Arruda L, Mayor R, Ng CK,
Weigelt B, Martínez-Ricarte F, Torrejon D, Oliveira M, Arias A,
Raventos C, Tang J, et al: Cerebrospinal fluid-derived circulating
tumour DNA better represents the genomic alterations of brain
tumours than plasma. Nat Commun. 6:88392015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pentsova EI, Shah RH, Tang J, Boire A, You
D, Briggs S, Omuro A, Lin X, Fleisher M, Grommes C, et al:
Evaluating cancer of the central nervous system through
next-generation sequencing of cerebrospinal fluid. J Clin Oncol.
34:2404–2415. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li Y, Pan W, Connolly ID, Reddy S, Nagpal
S, Quake S and Gephart MH: Tumor DNA in cerebral spinal fluid
reflects clinical course in a patient with melanoma leptomeningeal
brain metastases. J Neurooncol. 128:93–100. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Momtaz P, Pentsova E, Abdel-Wahab O,
Diamond E, Hyman D, Merghoub T, You D, Gasmi B, Viale A and Chapman
PB: Quantification of tumor-derived cell free DNA(cfDNA) by digital
PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600
mutated malignancies. Oncotarget. 7:85430–85436. 2016. View Article : Google Scholar : PubMed/NCBI
|
